SOURCE: Oracle Corporation

Oracle Corporation

March 25, 2015 08:01 ET

Alliance for Clinical Trials in Oncology Foundation Selects Oracle Health Sciences Cloud Solutions as the IT Platform for Its 10-Year Clinical Study

WASHINGTON, DC--(Marketwired - Mar 25, 2015) - ORACLE INDUSTRY CONNECT -- Oracle (NYSE: ORCL) -- Alliance for Clinical Trials in Oncology Foundation, a nonprofit organization that supports the mission to reduce the impact of cancer, has selected Oracle's Siebel Clinical Trial Management System and Oracle Health Sciences IRT as the IT platform for a comprehensive, 10-year clinical study, conducted in partnership with a tier-one pharmaceutical company and sponsored by Alliance Foundation Trials (AFT). The solutions will provide a proven platform for the decade-long study as well as future Alliance research initiatives.

"As part of our mission to reduce the impact of cancer, it is imperative that our clinical trials run as successfully and efficiently as possible. Going into a 10-year study, we need a proven, enterprise-scale clinical trial management infrastructure that we can count on today and into the future," said Monica M. Bertagnolli MD, president, Alliance for Clinical Trials in Oncology Foundation and chief executive officer, AFT. "Oracle Health Sciences applications provided a competitive solution."

Siebel Clinical Trial Management System will help AFT ensure the efficiency and integrity of its studies, reducing risk while boosting research team productivity. The organization plans to create a centralized trial management database that provides users with the most relevant information based on their specific roles and responsibilities and is designed to speed access to critical data, improve monitoring and patient safety, and keep data secure. Users can also access the system via any browser from any device, further elevating productivity and the user experience.

The deployment of Oracle Health Sciences IRT is designed to enable AFT to more effectively manage patient randomization and global supply chains by extending interactive voice response (IVR) and interactive web response (IWR) systems. AFT also expects to gain the insight needed to change study parameters midstream while reducing service delivery and change-order costs, and looks to optimize the cost of event charges by leveraging the web in addition to the phone for capture.

AFT will benefit from the scalability, cost-effectiveness, and rapid deployment that cloud-based solutions deliver. It plans to leverage Oracle Health Sciences Cloud for Oracle Health Sciences IRT and a third-party cloud service provider for Siebel Clinical Trial Management System.

"Oracle is pleased to support AFT as it embarks on this important 10-year research study. Oracle Health Sciences solutions provide a highly reliable foundation that helps to drive efficient, effective, and insightful research. Our flexible cloud-based delivery options are designed to help AFT achieve faster time to deployment, lower cost of entry, and ready scalability when needed," said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences.

Additional Information
Join the Oracle Health Sciences community on Facebook and follow @OracleHealthSci on Twitter.

About Oracle
Oracle engineers hardware and software to work together in the cloud and in your data center. For more information about Oracle (NYSE: ORCL), visit oracle.com.

About Alliance for Clinical Trials in Oncology Foundation
Alliance for Clinical Trials in Oncology Foundation raises funds to help Alliance for Clinical Trials in Oncology (part of the National Cancer Institute's National Clinical Trials Network) answer important treatment questions through large-scale clinical trials. The foundation also conducts research in breast, lung, prostate, and bladder cancer that is supported by nonfederal sources through the limited liability entity Alliance Foundation Trials, LLC (AFT). Learn more about the Alliance.

Trademark
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Contact Information